Literature DB >> 26136993

Expression of β-site APP-cleaving enzyme 1 in the hippocampal tissue of an insulin-resistant rat model of Alzheimer's disease.

Shize Li1, Nini Wang2, Jiyu Lou1, Xiaoman Zhang3.   

Abstract

The aim of this study was to investigate the expression of β-site APP-cleaving enzyme 1 (BACE1) in the hippocampal tissue of an insulin-resistant rat model, and thereby explore the roles of BACE1 and insulin resistance (IR) in the pathogenesis of Alzheimer's disease (AD). A total of 36 male Sprague-Dawley rats, aged 2 months, were randomly divided into three groups. These were an insulin-resistant (experimental) group, a high fat control group and a blank control group. The cognitive function and behavioral changes of the rats were tested by a Morris water maze experiment. Amyloid β (Aβ) deposition was detected by an immunohistochemical method. The expression levels of BACE1 in the rat hippocampal tissues were detected by enzyme-linked immunosorbent assay, western blotting and reverse transcription-quantitative polymerase chain reaction technology. The rats in the experimental group had evident learning and memory impairment, with significantly decreased learning memory. The modeling was successful; in the experimental group, the rats exhibited IR and their glucose metabolism was significantly abnormal. However, there was no characteristic pathology of AD. The expression of BACE1 in the brain tissue of rats in the experimental group was significantly higher than that in high fat control and blank control groups (P<0.01). In conclusion, the expression of BACE1 in the brain tissue of insulin-resistant rats increased, and IR was indicated to participate in the pathogenesis of AD.

Entities:  

Keywords:  Alzheimer's disease; expression; insulin resistance; β-site APP-cleaving enzyme 1

Year:  2015        PMID: 26136993      PMCID: PMC4473338          DOI: 10.3892/etm.2015.2391

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  24 in total

1.  Humanin attenuates Alzheimer-like cognitive deficits and pathological changes induced by amyloid β-peptide in rats.

Authors:  Gao-Shang Chai; Dong-Xiao Duan; Rong-Hong Ma; Jian-Ying Shen; Hong-Lian Li; Zhi-Wei Ma; Yu Luo; Lu Wang; Xin-Hua Qi; Qun Wang; Jian-Zhi Wang; Zelan Wei; Darrell D Mousseau; Li Wang; Gongping Liu
Journal:  Neurosci Bull       Date:  2014-11-12       Impact factor: 5.203

Review 2.  Lack of glucagon receptor signaling and its implications beyond glucose homeostasis.

Authors:  Maureen J Charron; Patricia M Vuguin
Journal:  J Endocrinol       Date:  2015-01-07       Impact factor: 4.286

3.  Effect of donepezil and lercanidipine on memory impairment induced by intracerebroventricular streptozotocin in rats.

Authors:  Swapnil Sonkusare; Krishnamoorthy Srinivasan; Chamanlal Kaul; Poduri Ramarao
Journal:  Life Sci       Date:  2005-05-20       Impact factor: 5.037

4.  Effects of sodium ferulate on amyloid-beta-induced MKK3/MKK6-p38 MAPK-Hsp27 signal pathway and apoptosis in rat hippocampus.

Authors:  Ying Jin; Ying Fan; En-zhi Yan; Zhuo Liu; Zhi-hong Zong; Zhi-min Qi
Journal:  Acta Pharmacol Sin       Date:  2006-10       Impact factor: 6.150

5.  Spatial and temporal control of age-related APP processing in genomic-based beta-secretase transgenic mice.

Authors:  Matthew J Chiocco; Bruce T Lamb
Journal:  Neurobiol Aging       Date:  2006-01-18       Impact factor: 4.673

Review 6.  beta-Secretase, APP and Abeta in Alzheimer's disease.

Authors:  Robert Vassar
Journal:  Subcell Biochem       Date:  2005

Review 7.  Targeting the β secretase BACE1 for Alzheimer's disease therapy.

Authors:  Riqiang Yan; Robert Vassar
Journal:  Lancet Neurol       Date:  2014-02-17       Impact factor: 44.182

8.  Promoter polymorphisms which modulate BACE1 expression are associated with sporadic Alzheimer's disease.

Authors:  Shan Wang; Jianping Jia
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-01-05       Impact factor: 3.568

9.  Soluble aβ promotes wild-type tau pathology in vivo.

Authors:  Meredith A Chabrier; Mathew Blurton-Jones; Andranik A Agazaryan; Joy L Nerhus; Hilda Martinez-Coria; Frank M LaFerla
Journal:  J Neurosci       Date:  2012-11-28       Impact factor: 6.167

10.  BACE1 inhibitor drugs in clinical trials for Alzheimer's disease.

Authors:  Robert Vassar
Journal:  Alzheimers Res Ther       Date:  2014-12-24       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.